je.st
news
Tag: anticancer
Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent FF-10501' For FUJIFILM In Patients With Advanced Hematologic Malignancies
2014-09-03 11:37:54| drugdiscoveryonline Home Page
Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS)
Tags: with
advanced
corporation
agent
Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen
2014-08-26 16:20:33| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Agreement to Combine Mercks Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizers crizotinib (XALKORI) in Clinical Trial WHITEHOUSE STATION, N.J. Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizers crizotinib (XALKORI) with Mercks investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC). Language: English read more
Tags: study
combination
evaluating
collaborate
Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP
2014-07-30 10:19:09| drugdiscoveryonline Home Page
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all
Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475
2014-02-05 12:40:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck Also to Initiate Phase I Signal Finding Study with MK-3475 in 20 New Cancer Types WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Mercks investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
combination
strategic
evaluate
MolMed a new patent on its anticancer NGR-hTNF
2013-09-11 20:07:47| Logistics - Topix.net
MolMed S.p.A. announces today receipt of the official notification from the European Patent Office of the decision to grant a patent covering the therapeutic use of its investigational anticancer drug NGR-hTNF at low doses.
Tags: patent
anticancer